DelveInsight’s, “Bacteremia Pipeline Insight 2023” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in the Bacteremia pipeline landscape. It covers the Bacteremia pipeline drug profiles, including Bacteremia clinical trials and nonclinical stage products. It also covers the Bacteremia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Bacteremia Pipeline treatment landscape of the report, click here @ Bacteremia Pipeline Outlook
Key Takeaways from the Bacteremia Pipeline Report
For further information, refer to the detailed Bacteremia Unmet Needs, Bacteremia Market Drivers, and Bacteremia Market Barriers, click here for Bacteremia Ongoing Clinical Trial Analysis
Bacteremia refers to the presence of live bacteria in the bloodstream. It can develop asymptomatically during routine activities such as brushing one’s teeth or following minor medical treatments. Release of bacterial toxins into the bloodstream, can trigger a strong immunological response, resulting in systemic inflammatory response syndrome. Another term which can be used for Bacteraemia is “Blood Poisoning”.
Request a sample and discover the recent advances in Bacteremia Ongoing Clinical Trial Analysis and Medications, click here @ Bacteremia Treatment Landscape
Bacteremia Emerging Drugs Profile
Ceftobiprole medocaril is the water-soluble prodrug of the pyrrolidinone cephalosporin, ceftobiprole. It is developed for IV administration. It exhibits extensive antibacterial action against Gram-positive and Gram-negative bacteria, including methicillin-resistant staphylococci, penicillin-resistant pneumococci, and Enterococcus faecalis. A unique combination of properties in ceftobiprole medocaril inhibits all transpeptidases, including the penicillin-binding protein (PBP) 2a. It is designed specifically to bind to this penicillin-resistant target. In January 2022 Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections. A phase 3 Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis.
Exebacase (CF301) is a lysine with potent activity against Staphylococcus aureus. It has the potential to become a new first-line treatment for patients with staphylococcal bacteremia. It targets a highly conserved region of the cell wall, which is important for bacteria, making it less likely that resistance will develop. When used in combination with SOC antibiotics, the result is a new therapeutic modality capable of addressing the high unmet clinical need for Staph aureus infections. It was the first and only lysine to enter a human clinical trial in the United States. Adding exebacase to vancomycin or daptomycin significantly increased survival in animal models of the disease compared with treatment with SOC antibiotics or exebacase alone. A Phase III Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis.
Dive deep into rich insights for drugs for Bacteremia Market Drivers and Bacteremia Market Barriers, click here @ Bacteremia Unmet Needs and Analyst Views
Bacteremia Pipeline Therapeutics Assessment
There are approx. 7+ Bacteremia companies which are developing the Bacteremia therapies. The Bacteremia companies which have their Bacteremia drug candidates in the most advanced stage, i.e. phase III include, Basilea Pharmaceutica.
Scope of the Bacteremia Pipeline Report
Got Queries? Find out the related information on Bacteremia Mergers and acquisitions, Bacteremia Licensing Activities @ Bacteremia Emerging Drugs, and Recent Trends
Table of Content
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services